Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients (CARES10)
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients
Sponsor: Kedrion S.p.A.
A PHASE3 clinical study on Primary Immunodeficiency Disease, this trial is completed. The trial is conducted by Kedrion S.p.A. and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
May 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — May 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2021 — Feb 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Oct 2020 [monthly]
Recruiting PHASE3
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kedrion S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .